The Landscape of Human Cancer Proteins Targeted by SARS-CoV-2

Cancer Discov. 2020 Jul;10(7):916-921. doi: 10.1158/2159-8290.CD-20-0559. Epub 2020 May 22.

Abstract

The mapping of SARS-CoV-2 human protein-protein interactions by Gordon and colleagues revealed druggable targets that are hijacked by the virus. Here, we highlight several oncogenic pathways identified at the host-virus interface of SARS-CoV-2 to enable cancer biologists to apply their knowledge for rapid drug repurposing to treat COVID-19, and help inform the response to potential long-term complications of the disease.

Publication types

  • Review

MeSH terms

  • Betacoronavirus*
  • COVID-19
  • Cell Cycle
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / genetics
  • Coronavirus Infections / metabolism
  • Coronavirus Infections / physiopathology
  • DNA Damage
  • Drug Repositioning*
  • Epigenomics
  • Humans
  • Neoplasm Proteins / antagonists & inhibitors*
  • Neoplasm Proteins / drug effects
  • Neoplasms / drug therapy*
  • Neoplasms / genetics
  • Neoplasms / metabolism
  • Neoplasms / physiopathology
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / genetics
  • Pneumonia, Viral / metabolism
  • Pneumonia, Viral / physiopathology
  • Protein Biosynthesis
  • SARS-CoV-2

Substances

  • Neoplasm Proteins